93 results about "Vasoactive" patented technology

Pharmaceutical compositions relating to vasoactive intestinal polypeptides and methods for the treatment of metabolic disorders, including diabetes, insulin resistance, metabolic acidosis and obesity are presented. Methods of using the vasoactive intestinal polypeptide compositions are also disclosed.

The invention provides compositions and methods suitable for ameliorating female sexual dysfunction, and in particular, female sexual arousal disorder. In preferred embodiments, the invention provides a semisolid composition suitable for topical application comprising: an effective amount of a vasoactive prostaglandin, a penetration enhancer, a polymer thickener, a lipophilic component, and an acidic buffer system. In other embodiments, the invention provides a method of treating female sexual arousal disorder by applying an effective dose of a topical semisolid prostaglandin composition to the anterior wall of the vagina.

The present invention is directed to compositions useful in treating or preventing ileus in a patient. The compositions of the invention include a pituitary adenylate cyclase activating peptide (PACAP) receptor antagonist and / or a vasoactive intestinal peptide (VIP) receptor antagonist in an amount sufficient to treat or prevent ileus in a patient. In one embodiment both a PACAP and VIP receptor antagonists are present, preferably in a combination that blocks vasoactive pituitary cyclase 1 (VPAC1), VPAC2 and pituitary adenylate cyclase 1 (PAC1) receptors. Methods of using such composition to treat or prevent ileus in a patient are also encompassed by the invention.

Pharmaceutical compositions relating to vasoactive intestinal polypeptides and methods for the treatment of metabolic disorders, including diabetes, insulin resistance, metabolic acidosis and obesity are presented. Methods of using the vasoactive intestinal polypeptide compositions are also disclosed.

Provided herein are methods for the induction of hypothermia and the treatment of clinical insults in a subject through the administration of a regulated hypothermic multidrug combination. The compositions or multidrug combinations of the invention comprise a regulated hypothermic compound or a dopamine receptor agonist; a vasoactive compound; and an antiarrhythmic compound or a serotonin 5-HT3 receptor antagonist. Additional agents can be included in the composition including at least one of an antioxidant, a vitamin, N-acetylcysteine, and an antihyperglycemic compound. The invention further recognizes that a two phase delivery of multidrug combinations, a rapid infusion of the composition to induce hypothermia followed by a period of slow infusion to maintain the hypothermic state for a sustained period of time. Using the two phase delivery method of the invention, the composition may comprise ethanol and, optionally, at least one of a vasoactive compound, an antiarrhythmic compound, a serotonin 5-HT3 receptor antagonist, an antioxidant, a vitamin, N-acetylcysteine, and an antihyperglycemic compound. This two phase delivery method can be used to deliver any of the compositions of the invention and provides significant benefits to a patient.

The invention discloses multi-target polypeptides of opium and neuropeptide FF receptors; amino acid substitution is performed based on an opium peptide Biphalin and an NPFF chimeric peptide BN-9, and a series of multi-target polypeptides which can activate various receptors of an opium and NPFF system at the same time are obtained. By in-vitro cAMP function identification and identification of body analgesic activity and central side effects and other pharmacological activities, the multi-target polypeptides are indicated to activate the opium and NPFF receptors at the same time, have high-efficiency analgesic activity and cannot generate the analgesic tolerance phenomenon, and moreover, have the advantages of showing low side effects on body temperature, gastrointestinal motility, cardiovascular activity and the like. Therefore, the multi-target polypeptides have high application value in preparation of clinical analgesic drugs.

The present invention provides an ex vivo vascular remodeling methods and system by which an excised, small diameter blood vessel can be harvested and expanded to provide viable vascular grafts, as demonstrated at the physical and molecular levels, and as optimized in vivo. The tissue-engineered vessels generated by the present invention closely resemble native vessels in terms of structure, histologically, including endothelial coverage and intricate structural components such as the internal elastic lamina, viability (as measured with the MTT assay and TUNEL analysis), and function (vasoactivity, mechanical and biomechanical properties). Thus, the resulting vascular grafts behave in a manner similar to native arteries in terms of mechanical integrity, and provide clinically relevant patency rates when implanted in vivo. Moreover, the ex vivo methods and system permit the precise control of the mechanical environment involving the excised vessel, while at the same time permitting careful monitoring of the resulting growth / remodeling, thereby opening new avenues of research regarding the mechanical stimuli responsible for specific aspects of remodeling in vivo.

The present invention is directed to compositions useful in treating or preventing ileus in a patient. The compositions of the invention include a pituitary adenylate cyclase activating peptide (PACAP) receptor antagonist and / or a vasoactive intestinal peptide (VIP) receptor antagonist in an amount sufficient to treat or prevent ileus in a patient. In one embodiment both a PACAP and VIP receptor antagonists are present, preferably in a combination that blocks vasoactive pituitary cyclase 1 (VPAC1), VPAC2 and pituitary adenylate cyclase 1 (PAC1) receptors. Methods of using such composition to treat or prevent ileus in a patient are also encompassed by the invention.

The invention provides new application of indole-3-carbinol, diindolylmethane and derivatives thereof to preparation of a medicine for preventing and controlling atherosclerosis (AS). The indole-3-carbinol, diindolylmethane and derivatives thereof have obvious effects of resisting oxidation and improving endothelial functions, can ensure that the expression and proportion of all vaso-active substances in a human body are normal and the endothelial functions can be recovered normally, and have the good effects of reducing blood fat, and resisting AS. Meanwhile, the active ingredients of the used small molecule medicines can be obtained easily, and the indole-3-carbinol, diindolylmethane and derivatives thereof are low in price, have stable performance and are convenient to store and transport, and have wide application prospect.

Pharmaceutical compositions relating to vasoactive intestinal polypeptides and methods for the treatment of metabolic disorders, including diabetes, insulin resistance, metabolic acidosis and obesity are presented. Methods of using the vasoactive intestinal polypeptide compositions are also disclosed.

The present invention relates to compositions of the polypeptide EEIIMID and one or more fibrinolytic agents selected from the group consisting of scuPA, tPA, uPA, tcuPA, streptokinase, rt-PA, alteplase, rt-PA derivatives, reteplase, lanoteplase, TNK-rt-PA, anisoylated plasminogen streptokinase complex, anistreplase, or a streptokinase derivative. The invention further relates to methods of enhancing the fibrinolytic activity, reducing the side effects due to vasoactivity caused by the fibrinolytic agents, or prolonging the half lives of the fibrinolytic agents by adding EEIIMD.

A caffeciate type compound, erigeron ester B, used as the medicine for treating cardiovascular and cerebrovascular diseases is prepared from the dried herb of erigeron breviscapus through extracting and separating.

This invention relates to the non-invasive determination of the degree of vasoactivity in the microcirculation in a tissue caused by a drug, disease, injury normal or pathological regulation. More specifically, the invention relates to a method of determining the influence on microcirculation in living tissue from an irritative agent, drugs, disease, injuries normal or pathological regulation including, illuminating a tissue surface with polarized light, collecting the backscattered light through a polarizing filter, detecting the backscattered and polarized light by a photo-sensitive array, transferring the collected information in digital form to a computing device, separating the collected information into at least two data matrixes, each representing a specific wavelength range and generating an output data matrix by processing corresponding values in at least two data matrixes by an algorithm, wherein each value in said output data matrix represents the amount of influence on the microcirculation in a source point of the tissue. Thereby a representation of the tissue microcirculation is obtained.

Described herein are methods and compositions comprising a compound of formula (I), e.g., dehydro-alpha-lapachone, or an analog, derivative, isomer, prodrug, or pharmaceutically acceptable salt thereof, for treatment and / or prevention of angiogenic- or vascular-associated diseases or disorders. The compound has anti-vascular activity. In some embodiments, the compound has anti-vascular activity that targets pathways other than VEGF pathways. In some embodiments, the compound or the composition further comprises anti-tumor activity. In some embodiments, the compound or the composition can decrease adhesion or motility of at least one cell (e.g., endothelial cells or cancer cells).

The invention relates to a method and a pharmaceutical combination for the treatment of CNS disorders, which includes at least a first compound having therapeutic effect on the CNS, and a second compound which facilitates penetration through the hematoencephalic barrier of the former. The second compound is administered endonasally, and has refectory (mainly neuro- and vasoactive) effects over structures and receptors of nasal mucous membrane, mainly receptors of vomeronasal systems and trifacial nerve.

A method for screening a patient for angioinhibition resistance and treating said patient having a disease susceptible to treatment via an anti-angiogenic agent. The screening method includes an assay for identifying the presence of angioinhibition resistance in patients by collecting patient blood or serum and subjecting it to a Chick Chorioallantoic Membrane (CAM) angiogenesis assay configured for accepting a human tumor wherein the human tumor xenograft includes a vasculature system. The screening method and assay further includes steps that include using the CAM results for identifying the endogenous pro-angiogenic non-peptide hormone concentrations of the blood sample by calculating the vascular activity of the vasculature system of the human tumor xenograft in the presence of anti-angiogenic drugs and inducing in the patient, a state of subclinical hypothyroidism prior to commencing anti-angiogenic treatment.

The present invention provides an ex vivo vascular remodeling methods and system by which an excised, small diameter blood vessel can be harvested and expanded to provide viable vascular grafts, as demonstrated at the physical and molecular levels, and as optimized in vivo. The tissue-engineered vessels generated by the present invention closely resemble native vessels in terms of structure, histologically, including endothelial coverage and intricate structural components such as the internal elastic lamina, viability (as measured with MTT assay and TUNEL analysis), and function (vasoactivity, mechanical and biomechanical properties). Thus, the resulting vascular grafts behave in a manner similar to native arteries in terms of mechanical integrity, and provide clinically relevant patency rates when implanted in vivo. Moreover, the ex vivo methods and system permit the precise control of the mechanical environment involving the excised vessel, while at the same time permitting carefully monitoring of the resulting growth / remodeling, thereby opening new avenues of research regarding the mechanical stimuli responsible for specific aspects of remodeling in vivo.

The present invention relates to the preparation of a Cynara scolymus extract obtainable by fractioning on a resin. The process of the invention allows to obtain an extract, starting from the aerial parts of the plant Cynara scolymus, containing three classes of active principles, namely dicaffeoylquinic acids, luteolin and cynaropicrin glycosides, in a constant ratio. Cynaropicrin is stabilized by addition of precise amounts of sulfated amino acids or suitable thio-derivatives. These extracts have hypolipemizing, anti-dyspeptic and vascular anti-inflammatory activities. The extracts are mainly formulated in Enothera biennis oil or in oils rich in ω-3 and ω-6 acids which enhance the vascular activity.

The invention discloses three compounds of hydroxide radical methyl ophiopogonanone B (hereinafter referred as 6), 2Belta-hydroxide radical methyl ophiopogonanone A (hereinafter referred as 7a) and 2Alpha- hydroxide radical methyl ophiopogonanone A (hereinafter referred as 7b) for SMI and the preparation method thereof. The invention also discloses a method for controlling the quality of the SMI so as to control the compound 6, 7a and 7b and active compound methyl ophiopogonanone B (hereinafter referred as 5), ophiopogonin A (hereinafter referred as 8) and ginsenoside Rb1 with a fixed quantity. A plurality of researches prove that the components can be the main active substances of caring cardiovascular disease through the SMI. As the invention is added with ophiopogon angiocarpy active ingredient as a quality control standard, the quality of the SMI product is more stable and reliable when compared with the traditional quality control art, thereby fundamentally solving the problem of being unbeneficial for the quality control of the ophiopogon part during the traditional SMI production process.

Pharmaceutical compositions relating to vasoactive intestinal polypeptides and methods for the treatment of metabolic disorders, including diabetes, insulin resistance, metabolic acidosis and obesity are presented. Methods of using the vasoactive intestinal polypeptide compositions are also disclosed.

The invention relates to a natural high-polymer bioactive trauma repair material with a function of releasing active ions and a method for preparing the natural high-polymer bioactive trauma repair material. The method includes soaking natural high-polymer materials in silicate extract liquid for a period of time; taking the natural high-polymer materials out of the silicate extract liquid and drying the natural high-polymer materials to obtain the natural high-polymer bioactive trauma repair material with the function of controllably releasing the ions. The natural high-polymer bioactive trauma repair material and the method have the advantages that the natural high-polymer bioactive trauma repair material is creatively prepared by the aid of silicate extract liquid permeating processes, aqueous solution is used as a medium, silicate components with angiogenesis activity can be uniformly dispersed inside the natural high-polymer materials, granular agglomeration can be prevented, and accordingly the natural high-polymer bioactive trauma repair material which is a bioactive composite trauma repair material can be prepared; the inorganic ions are uniformly adsorbed and distributed in high-polymer matrixes, and the ion release concentration can be controlled.

The present invention relates to compositions for topical delivery of one or more vasoactive vitamins and their methods of preparation and use. More specifically, the composition includes one or more vasoactive vitamins, one or more alkyl hydroxybenzoate preservatives, an alkanol solvent, an alkoxylated alcohol humectant, and a high molecular weight hydrophilic colloid viscosity increasing agent. In various embodiments, the vasoactive vitamins include vitamin B3 compounds.

The invention discloses application of coptisine shown as general formula (I) as shown in the specification and pharmaceutically acceptable salt of the coptisine in preparing a medicine for preventing and / or treatingSLE (systemic lupus erythematosus) and complications of SLE.The application has the benefits that the coptisine has pharmacological actions of reducing an in-vivo autoantibody expression level of a mouse with lupus, improving an immunologic function, reducing immune complex sedimentation in a kidney tissue of the mouse with the lupus and improving a kidney function of the mouse with the lupus, and effects of protecting a spleen function of the mouse with the lupus, protecting a vascular endothelium function of the mouse with the lupus, reducing blood pressure and improving vascular activity of the mouse with the lupus.The coptisine is a monomeric compound extracted from a common traditional Chinese medicine, namely rhizoma coptidis, has the advantages of low toxicity, simple extraction technology and the like, is wide in raw material resource, has good application and development prospects and is a relatively perfect novel traditional Chinese medicine monomer for treating the SLE, and the complications of the SLE such as immune dysfunction, lupus nephritis, lupus spleen injury, lupus atherosclerosis and lupus hypertension.

The invention relates to a medicine for treating chilblain. The medicine is prepared by taking pearl cream, Vaseline, starch, talcum powder or distilled water as a substrate and preparing following raw medicines into an ointment or liquid according to mass percentage: 0.1-5% of anisodamine and 0.1-5% of nitrendipine. With the adoption of the medicine for treating the chilblain, the anisodamine is taken as a blood vessel active medicine and has an expansion functions on arterioles, venule and blood capillaries, so that microcirculation can be improved; the nitrendipine is used as a calcium ion antagonist and has a selective expansion function on the venule of the peripheral blood vessels; and the anisodamine and nitrendipine are combined to have obvious improvement on blood supply of a chilblain part, so as to have the effect of preventing and treating the chilblain.

This invention relates to the non-invasive determination of the degree of vasoactivity in the microcirculation in a tissue caused by a drug, disease, injury normal or pathological regulation. More specifically, the invention relates to a method of determining the influence on microcirculation in living tissue from an irritative agent, drugs, disease, injuries normal or pathological regulation including, illuminating a tissue surface with polarized light, collecting the backscattered light through a polarizing filter, detecting the backscattered and polarized light by a photo-sensitive array, transferring the collected information in digital form to a computing device, separating the collected information into at least two data matrixes, each representing a specific wavelength range and generating an output data matrix by processing corresponding values in at least two data matrixes by an algorithm, wherein each value in said output data matrix represents the amount of influence on the microcirculation in a source point of the tissue. Thereby a representation of the tissue microcirculation is obtained.

The invention provides a series of open-loop abietane diterpene compounds or pharmaceutical salts thereof, pharmaceutical compositions composed of the compounds as effective ingredients and at least one pharmaceutically acceptable carrier, and a preparation method and an application of the compounds or the pharmaceutical salts thereof in preparation of drugs or functional foods for prevention and(or) treatment of hypertension, heart disease, myocardial ischemia, stroke and other cardiovascular and cerebrovascular diseases. The compounds 1-8 are novel open-loop abietane diterpene compounds, have significant vasodilation activity on KCl preshrunk rat thoracic aorta, have a novel chemical structure, and have many advantages as vasodilation drugs. The compounds 9 and 10 are known compounds, also have significant vasodilating effects on KCl preshrunk rat thoracic aorta, and have no reports in vasodilation at present.

A 5G IoT-based financial payment drone smart medical system comprises a solar first aid kit, a smart medical flight case, a smart medical dispatch center, a 121 distress WeChat mini program, an emergency room drone, a drone pickup pole, and an AprilTag mark. The solar first aid kit is configured to carry and remotely control an AED drone. A solar cell is outside a fixed side surface. The AED droneincludes a wireless charging module and is configured to deliver an AED to the residence or the onset location of a patient; the smart medical flight case comprises an AED smart medical flight case and an emergency room smart medical flight case and is configured to carry the AED and vasoactive drugs. The 121 distress WeChat mini program includes a pressure parameter client, a quick rescue unit,a heartbeat detection unit, a distress information area, and a medical assistance unit. The system can make most of the sudden cardiac death patients in the city obtain the treatment of vasoactive drugs, CPR and AED in 4 minutes under the guidance of professional first aid.

A method and system for creating shear stress and endothelial mechanotransduction through neuromuscular stimulation of the muscle pump. Chronic application a minimum of 30 days triggers the autocrine and paracrine processes which elevates production of vasoactive substances including nitric oxide, prostacyclin, superoxide dismutase, thrombomodulin, glutathion, Krupple-like factor 2 and many others. Chronic application also promotes angiogenesis and development of collateral circulation. This is a cost-effective, non-invasive, drug-free therapy to treat vascular dysfunction and ameliorate or reverse its effects on cardiovascular health.

The invention discloses benzimidazole derivative, belonging to the field of the medicinal chemistry. The invention also discloses a preparation method of the benzimidazole derivative, the medicinal composition containing the compound of benzimidazole derivative and the application of the compound of benzimidazole derivative to the treatment of hypertension and congestive heart failure and the treatment of other diseases through doubly blocking angiotensin II (AT1) receptor and endothelin (ETA) receptors.

The present invention relates to compositions of the polypeptide EEIIMI, anti-LRP antibodies, LRP antagonists, and / or one or more fibrinolytic agents comprising scuPA, tPA, uPA, tcuPA, streptokinase, rt-PA, alteplase, rt-PA derivatives, reteplase, lanoteplase, TNK-rt-PA, anisoylated plasminogen streptokinase complex, anistreplase, or a streptokinase derivative. The invention further relates to methods of enhancing the fibrinolytic activity, reducing the side effects due to vasoactivity caused by the fibrinolytic agents, and / or prolonging the half lives of the fibrinolytic agents.